RA Capital Increases Stake with $11.1M Stock Purchases, Now Owns 36.6% of Artiva Biotherapeutics
ARTV has more than doubled off its 52-week low of $1.47.
Summary
RA Capital Management, a major institutional investor with board representation, reported additional open market purchases of Artiva Biotherapeutics common stock totaling $11.1 million, increasing its beneficial ownership to 36.6%.
Key Events · Ownership and Investor Activity · ARTV
-
Major Shareholder Accumulation
RA Capital Management, L.P. and its affiliates purchased an additional 1,434,155 shares of common stock through open market transactions.
-
Significant Investment
The purchases, made between June 9 and June 15, 2026, totaled approximately $11.1 million.
-
Increased Ownership Stake
RA Capital's beneficial ownership in Artiva Biotherapeutics, Inc. now stands at 17,811,623 shares, representing 36.6% of the company's outstanding common stock.
-
Ongoing Institutional Support
This filing continues a pattern of significant accumulation by major institutional investors, including RA Capital and GC Corp., as seen in recent filings.
Analysis · ARTV · Life Sciences
This Schedule 13D/A reports significant additional open market purchases by RA Capital Management, a major institutional investor with board representation. The $11.1 million in new purchases, following a recent $300 million public offering and positive clinical data, represents a strong vote of confidence in Artiva Biotherapeutics' prospects. RA Capital's increased stake to 36.6% reinforces the ongoing pattern of institutional accumulation, suggesting deep conviction in the company's long-term value.
At the time of this filing, ARTV was trading at $9.37 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $226.9M. The 52-week trading range was $1.47 to $14.53. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.